EA Pharma (Japan)

Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan

Inebilizumab is used in Japan for relapse prevention in aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). Nationwide post-marketing surveillance (PMS) is underway to evaluate the real-world safety and effectiveness of inebilizumab in Japanese pa...

Current Status of Bowel Preparation for Colonoscopy in Japan: A Web‐Based Survey of Endoscopists (PRESS Survey)

ABSTRACT Objectives The increasing number of patients with colorectal cancer underscores the importance of colonoscopy. Adequate bowel preparation is essential to ensure the quality and safety of colonoscopic examinations; however, data on the current practices in Japan remain li...